Phenylpropanolamine

Template:Short description Template:Use dmy dates Template:Cs1 config Template:Main other {{#invoke:Infobox|infobox}}Template:Template other{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= biosimilars= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= container_only= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= DTXSID= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= class6= component1= component2= component3= component4= component5= component6= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= image_class= image_class2= image_classL= image_classR= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_AU_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= DTXSID2= QID= QID2=PLLR= pregnancy_US= pregnancy_US_comment= |cat=Pages using infobox drug with unknown parameters |format=0|errNS=0

|preview=

}}{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals={{#invoke:ParameterCount |main |component1 |component2 |component3 |component4|component5|component6 }} | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=91311O[C@H](c1ccccc1)[C@@H](N)C1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m0/s1DLNKOYKMWOXYQA-CBAPKCEASA-NTemplate:StdinchiciteTemplate:Stdinchicite | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.com B2By mouthMany<ref name="IndexNominum2000" /><ref name="Drugs.com" />R01Template:ATCvet | _legal_data=S4<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>F3Schedule VIRx-Only

| _other_data=(1RS,2SR)-2-amino-1-phenylpropan-1-ol

| _image_0_or_2 = Phenylpropanolamine.svgPhenylpropanolamine molecule ball.png | _image_LR =

| _datapage = Phenylpropanolamine (data page) | _vaccine_target={{#ifeq: | vaccine | | _type_not_vaccine }} | _legal_all=S4F3Schedule VI | _ATC_prefix_supplemental=R01Template:ATCvet | _has_EMA_link = | CAS_number=14838-15-4 | PubChem=4786 | ChemSpiderID=9875 | ChEBI= | ChEMBL=136560 | DrugBank=DB00397 | KEGG=D08368 | _hasInChI_or_Key={{#if:1S/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m0/s1DLNKOYKMWOXYQA-CBAPKCEASA-N |yes}} | UNII=33RU150WUN | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs={{#invoke:ParameterCount |main |CAS_number2 |ATC_prefix2 |PubChem2 |PubChemStructure2 |IUPHAR_ligand2 |DrugBank2 |ChemSpiderID2 |UNII2 |KEGG2 |ChEBI2 |ChEMBL2 |PDB_ligand2 |NIAID_ChemDB2 |SMILES2 |smiles2 |StdInChI2 |StdInChIKey2 |DTXCID2}} | _countIndexlabels={{#invoke:ParameterCount |main |index_label |index2_label}} | _trackListSortletter= |QID = |QID2 = |Verifiedfields= |Watchedfields=verified |verifiedrevid=464201364}} Phenylpropanolamine (PPA), sold under many brand names, is a sympathomimetic agent used as a decongestant and appetite suppressant.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="MortonHall2012" /><ref name="Ioannides-DemosProiettoTonkin2006">Template:Cite journal</ref> It was once common in prescription and over-the-counter cough and cold preparations. The medication is taken orally.<ref name="KanferDowseVuma1993" /><ref name="SalernoJacksonBerbano2005" />

Side effects of phenylpropanolamine include increased heart rate and blood pressure.<ref name="JohnsonHricik1993" /><ref name="ODonnell1995" /><ref name="Aaron1990" /><ref name="SalernoJacksonBerbano2005" /> Rarely, PPA has been associated with hemorrhagic stroke.<ref name="Ioannides-DemosProiettoTonkin2006" /><ref name="YoonBaeHong2007" /><ref name="JohnsonHricik1993" /> PPA acts as a norepinephrine releasing agent, indirectly activating adrenergic receptors.<ref name="RothmanBaumann2006">Template:Cite journal</ref><ref name="RothmanBaumann2005">Template:Cite journal</ref><ref name="RothmanVuPartilla2003">Template:Cite journal</ref> As such, it is an indirectly acting sympathomimetic.<ref name="RothmanBaumann2006" /><ref name="RothmanBaumann2005" /><ref name="RothmanVuPartilla2003" /><ref name="MortonHall2012" /> It was once thought to act as a sympathomimetic with additional direct agonist action on adrenergic receptors, but this proved wrong.<ref name="RothmanBaumann2006" /><ref name="RothmanBaumann2005" /><ref name="RothmanVuPartilla2003" /> Chemically, phenylpropanolamine is a substituted amphetamine and is closely related to ephedrine, pseudoephedrine, amphetamine, and cathinone.<ref name="LemkeWilliams2008" /><ref name="Johnson1991" /><ref name="Bravo1998">Template:Cite journal</ref><ref name="Ioannides-DemosProiettoTonkin2006" /> It is usually a racemic mixture of the (1R,2S)- and (1S,2R)-enantiomers of β-hydroxyamphetamine and is also known as dl-norephedrine.<ref name="Johnson1991" /><ref name="Elks2014" /><ref name="IndexNominum2000" />

Phenylpropanolamine was first synthesized around 1910 and its effects on blood pressure were characterized around 1930.<ref name="Johnson1991" /><ref name="Ioannides-DemosProiettoTonkin2006" /> It was introduced as medicine by the 1930s.<ref name="Mersfelder2001" /><ref name="Ioannides-DemosProiettoTonkin2006" /> It was withdrawn from many markets starting in 2000 after learning that it was associated with increased risk of hemorrhagic stroke.<ref name="Mersfelder2001">Template:Cite journal</ref><ref name="Ioannides-DemosProiettoTonkin2006" /> It was previously available both over-the-counter and by prescription.<ref name="Mersfelder2001" /><ref name="Drugs.com" /><ref name="Drugs@FDA" /><ref name="DailyMed-Search" /> Phenylpropanolamine is available for both human and/or veterinary use in some countries.<ref name="Drugs.com" />

Medical uses

Phenylpropanolamine is used as a decongestant to treat nasal congestion.<ref name="JohnsonHricik1993">Template:Cite journal</ref><ref name="ODonnell1995">Template:Cite journal</ref> It has also been used to suppress appetite and promote weight loss in the treatment of obesity and has shown effectiveness for this indication.<ref name="CoulterRebelloGreenway2018">Template:Cite journal</ref><ref name="Ioannides-DemosProiettoMcNeil2005">Template:Cite journal</ref><ref name="GreenwayHerberRaum1999">Template:Cite journal</ref>

Available forms

Phenylpropanolamine was previously available in the United States over-the-counter and in certain combination drug forms by prescription.<ref name="Drugs@FDA">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="DailyMed-Search">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> One such example of the latter was a combination of phenylpropanolamine and chlorpheniramine, which dually contained decongestant and antihistamine effects, marketed by Tutag as 'Vernate'. These forms have all been discontinued in the U.S., although.<ref name="Drugs@FDA" /><ref name="DailyMed-Search" /><ref name="Drugs.com" /> phenylpropanolamine remains available in some countries.<ref name="Drugs.com" />

Side effects

Phenylpropanolamine produces sympathomimetic effects and can cause side effects such as increased heart rate and blood pressure.<ref name="JohnsonHricik1993" /><ref name="ODonnell1995" /><ref name="Aaron1990">Template:Cite journal</ref><ref name="SalernoJacksonBerbano2005">Template:Cite journal</ref> It has been associated rarely with incidence of hemorrhagic stroke.<ref name="Mersfelder2001" /><ref name="YoonBaeHong2007" /><ref name="JohnsonHricik1993" />

Certain drugs increase the chances of déjà vu occurring in the user, resulting in a strong sensation that an event or experience currently being experienced has already been experienced in the past. Some pharmaceutical drugs, when taken together, have also been implicated in the cause of déjà vu.<ref>Template:Cite journal</ref> The [[Journal of Clinical Neuroscience|Template:Em]] reported the case of an otherwise healthy male who started experiencing intense and recurrent sensations of déjà vu upon taking the drugs amantadine and phenylpropanolamine together to relieve flu symptoms.<ref>Template:Cite journal</ref> He found the experience so interesting that he completed the full course of his treatment and reported it to the psychologists to write up as a case study. Because of the dopaminergic action of the drugs and previous findings from electrode stimulation of the brain,<ref>Template:Cite journal</ref> it was speculated that déjà vu occurs as a result of hyperdopaminergic action in the mesial temporal areas of the brain.

Interactions

There has been very little research on drug interactions with phenylpropanolamine.<ref name="KanferDowseVuma1993" /> In one study, phenylpropanolamine taken with caffeine was found to quadruple caffeine levels.<ref name="KanferDowseVuma1993" /> In another study, phenylpropanolamine reduced theophylline clearance by 50%.<ref name="KanferDowseVuma1993" />

Pharmacology

Pharmacodynamics

Phenylpropanolamine acts primarily as a selective norepinephrine releasing agent.<ref name="RothmanVuPartilla2003" /> It also acts as a dopamine releasing agent with around 10-fold lower potency.<ref name="RothmanVuPartilla2003" /> The stereoisomers of the drug have only weak or negligible affinity for α- and β-adrenergic receptors.<ref name="RothmanVuPartilla2003" />

Template:Nowrap

Compound	Template:Abbrlink	Template:Abbrlink	Template:Abbrlink	Ref
Dextroamphetamine (S(+)-amphetamine)	6.6–7.2	5.8–24.8	698–1,765	<ref name="RothmanBaumannDersch2001">Template:Cite journal</ref><ref name="BaumannPartillaLehner2013">Template:Cite journal</ref>
S(–)-Cathinone	12.4	18.5	2,366	<ref name="RothmanVuPartilla2003" />
Ephedrine ((–)-ephedrine)	43.1–72.4	236–1,350	>10,000	<ref name="RothmanBaumannDersch2001" />
(+)-Ephedrine	218	2,104	>10,000	<ref name="RothmanBaumannDersch2001" /><ref name="RothmanVuPartilla2003" />
Dextromethamphetamine (S(+)-methamphetamine)	12.3–13.8	8.5–24.5	736–1,292	<ref name="RothmanBaumannDersch2001" /><ref name="BaumannAyestasPartilla2012">Template:Cite journal</ref>
Levomethamphetamine (R(–)-methamphetamine)	28.5	416	4,640	<ref name="RothmanBaumannDersch2001" />
(+)-Phenylpropanolamine ((+)-norephedrine)	42.1	302	>10,000	<ref name="RothmanVuPartilla2003" />
(–)-Phenylpropanolamine ((–)-norephedrine)	137	1,371	>10,000	<ref name="RothmanVuPartilla2003" />
Cathine ((+)-norpseudoephedrine)	15.0	68.3	>10,000	<ref name="RothmanVuPartilla2003" />
(–)-Norpseudoephedrine	30.1	294	>10,000	<ref name="RothmanVuPartilla2003" />
(–)-Pseudoephedrine	4,092	9,125	>10,000	<ref name="RothmanVuPartilla2003" />
Pseudoephedrine ((+)-pseudoephedrine)	224	1,988	>10,000	<ref name="RothmanVuPartilla2003" />
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs: <ref name="RothmanBaumann2003">Template:Cite journal</ref><ref name="RothmanBaumann2006" />

Phenylpropanolamine was originally thought to act as a direct agonist of adrenergic receptors and hence to act as a mixed acting sympathomimetic,<ref name="Johnson1991" /><ref name="Bravo1998" /> However, phenylpropanolamine was subsequently found to show only weak or negligible affinity for these receptors and has been instead characterized as exclusively an indirectly acting sympathomimetic.<ref name="MortonHall2012" /><ref name="RothmanBaumann2006" /><ref name="RothmanBaumann2005" /><ref name="RothmanVuPartilla2003" /> It acts by inducing norepinephrine release and thereby indirectly activating adrenergic receptors.<ref name="RothmanBaumann2006" /><ref name="RothmanBaumann2005" /><ref name="RothmanVuPartilla2003" />

Many sympathetic hormones and neurotransmitters are based on the phenethylamine skeleton, and function generally in "fight or flight" type responses, such as increasing heart rate, blood pressure, dilating the pupils, increased energy, drying of mucous membranes, increased sweating, and a significant number of additional effects.Template:Citation needed

Phenylpropanolamine has relatively low potency as a sympathomimetic.<ref name="Johnson1991" /> It is about 100 to 200Template:Nbsptimes less potent than epinephrine (adrenaline) or norepinephrine (noradrenaline) in its sympathomimetic effects, although responses are variable depending on tissue.<ref name="Johnson1991" />

Pharmacokinetics

Absorption

Phenylpropanolamine is readily- and well-absorbed with oral administration.<ref name="BouchardWeberGeiger2002" /><ref name="GentileFridaySkoner2000" /><ref name="ChuaBenrimojTriggs1989">Template:Cite journal</ref> Immediate-release forms of the drug reached peak levels about 1.5Template:Nbsphours (range 1.0 to 2.3Template:Nbsphours) following administration.<ref name="KanferDowseVuma1993" /><ref name="GentileFridaySkoner2000">Template:Cite journal</ref> Conversely, extended-release forms of phenylpropanolamine reach peak levels after 3.0 to 4.5Template:Nbsphours.<ref name="KanferDowseVuma1993" /> The pharmacokinetics of phenylpropanolamine are linear across an oral dose range of 25 to 100Template:Nbspmg.<ref name="KanferDowseVuma1993" /> Steady-state levels of phenylpropanolamine are achieved within 12Template:Nbsphours when the drug is taken once every 4Template:Nbsphours.<ref name="KanferDowseVuma1993" /> There is 62% accumulation of phenylpropanolamine at steady state in terms of peak levels, whereas area-under-the-curve levels are not increased with steady state.<ref name="KanferDowseVuma1993" />

Distribution

The volume of distribution of phenylpropanolamine is 3.0 to 4.5Template:NbspL/kg.<ref name="KanferDowseVuma1993" /> Levels of phenylpropanolamine in the brain are about 40% of those in the heart and 20% of those in the lungs.<ref name="BouchardWeberGeiger2002" /> The hydroxyl group of phenylpropanolamine at the β carbon increases its hydrophilicity, reduces its permeation through the blood–brain barrier, and limits its central nervous system (CNS) effects.<ref name="BouchardWeberGeiger2002" /> Hence, phenylpropanolamine crosses into the brain only to some extent, has only weak CNS effects, and most of its effects are peripheral.<ref name="ODonnell1995" /><ref name="BouchardWeberGeiger2002" /><ref name="ChuaBenrimojTriggs1989" /><ref name="Johnson1991" /> In any case, phenylpropanolamine can produce amphetamine-like psychostimulant effects at very high doses.<ref name="Johnson1991" /><ref name="BouchardWeberGeiger2002" /><ref name="ChuaBenrimojTriggs1989" /> Phenylpropanolamine is more lipophilic than structurally related sympathomimetics with hydroxyl groups on the phenyl ring like epinephrine (adrenaline) and phenylephrine and has greater brain permeability than these agents.<ref name="ChuaBenrimojTriggs1989" /><ref name="Bravo1998" />

The plasma protein binding of phenylpropanolamine is approximately 20%.<ref name="ChuaBenrimojTriggs1989" /><ref name="KanferDowseVuma1993" /> However, it has been said that no recent studies have substantiated this value.<ref name="KanferDowseVuma1993" />

Metabolism

Phenylpropanolamine is not substantially metabolized.<ref name="GentileFridaySkoner2000" /><ref name="ChuaBenrimojTriggs1989" /> It also does not undergo significant first-pass metabolism.<ref name="GentileFridaySkoner2000" /> Only about 3 to 4% of an oral dose of phenylpropanolamine is metabolized.<ref name="ChuaBenrimojTriggs1989" /> Metabolites include hippuric acid (via oxidative deamination of the side chain) and 4-hydroxynorephedrine (via para-hydroxylation).<ref name="KanferDowseVuma1993" /><ref name="ChuaBenrimojTriggs1989" /><ref name="BouchardWeberGeiger2002" /> The methyl group at the α carbon of phenylpropanolamine blocks metabolism by monoamine oxidases (MAOs).<ref name="BouchardWeberGeiger2002" /><ref name="ChuaBenrimojTriggs1989" /><ref name="ODonnell1995">Template:Cite journal</ref> Phenylpropanolamine is also not a substrate of catechol O-methyltransferase.<ref name="ODonnell1995" /> The hydroxyl group at the β carbon of phenylpropanolamine also helps to increase metabolic stability.<ref name="ChuaBenrimojTriggs1989" />

Elimination

Approximately 90% of a dose of phenylpropanolamine is excreted in the urine unchanged within 24Template:Nbsphours.<ref name="KanferDowseVuma1993" /><ref name="BouchardWeberGeiger2002" /><ref name="GentileFridaySkoner2000" /><ref name="ChuaBenrimojTriggs1989" /> About 4% of excreted material is in the form of metabolites.<ref name="KanferDowseVuma1993" />

The elimination half-life of immediate-release phenylpropanolamine is about 4Template:Nbsphours, with a range in different studies of 3.7 to 4.9Template:Nbsphours.<ref name="BouchardWeberGeiger2002" /><ref name="GentileFridaySkoner2000" /><ref name="KanferDowseVuma1993">Template:Cite journal</ref> The half-life of extended-release phenylpropanolamine has ranged from 4.3 to 5.8Template:Nbsphours.<ref name="KanferDowseVuma1993" />

The elimination of phenylpropanolamine is dependent on urinary pH.<ref name="KanferDowseVuma1993" /><ref name="ChuaBenrimojTriggs1989" /> At a more acidic urinary pH, the elimination of phenylpropanolamine is accelerated and its half-life and duration are shortened, whereas at more basic urinary pH, the elimination of phenylpropanolamine is reduced and its half-life and duration are extended.<ref name="ChuaBenrimojTriggs1989" /><ref name="KanferDowseVuma1993" /> Urinary acidifying agents like ascorbic acid and ammonium chloride can increase the excretion of and thereby reduce exposure to amphetamines including phenylpropanolamine, whereas urinary alkalinizing agents including antacids like sodium bicarbonate as well as acetazolamide can reduce the excretion of these agents and thereby increase exposure to them.<ref name="GłowackaWiela-Hojeńska2021">Template:Cite journal</ref><ref name="ChuaBenrimojTriggs1989" /><ref name="PatrickMarkowitz1997">Template:Cite journal</ref>

Total body clearance of phenylpropanolamine has been reported to be 0.546Template:NbspL/h/kg, while renal clearance was 0.432Template:NbspL/h/kg.<ref name="KanferDowseVuma1993" />

Miscellaneous

As phenylpropanolamine is not extensively metabolized, it would probably not be affected by hepatic impairment.<ref name="KanferDowseVuma1993" /> Conversely, there is likely to be accumulation of phenylpropanolamine with renal impairment due to its dependence on urinary excretion.<ref name="KanferDowseVuma1993" />

Norephedrine is a minor metabolite of amphetamine and methamphetamine, as shown below.<ref name="KanferDowseVuma1993" /> It is also a minor metabolite of ephedrine and a major metabolite of cathinone.<ref name="KanferDowseVuma1993" /><ref name="BouchardWeberGeiger2002" /><ref name="ChuaBenrimojTriggs1989" />

Chemistry

File:Phenylpropanolamine spacefill.png

Space-filling model of phenylpropanolamine.

Phenylpropanolamine, also known as (1RS,2SR)-α-methyl-β-hydroxyphenethylamine or as (1RS,2SR)-β-hydroxyamphetamine, is a substituted phenethylamine and amphetamine derivative.<ref name="Elks2014" /><ref name="LemkeWilliams2008">Template:Cite book</ref><ref name="King2009">Template:Cite book</ref> It is closely related to the cathinones (β-ketoamphetamines).<ref name="LemkeWilliams2008" /> β-Hydroxyamphetamine exists as four stereoisomers, which include d- (dextrorotatory) and l-norephedrine (levorotatory), and d- and l-norpseudoephedrine.<ref name="King2009" /><ref name="MortonHall2012" /> d-Norpseudoephedrine is also known as cathine,<ref name="Elks2014" /><ref name="King2009" /> and is found naturally in Catha edulis (khat).<ref name="pmid19921126">Template:Cite journal</ref> Pharmaceutical drug preparations of phenylpropanolamine have varied in their stereoisomer composition in different countries, which may explain differences in misuse and side effect profiles.<ref name="MortonHall2012" /> In any case, racemic dl-norephedrine, or (1RS,2SR)-phenylpropanolamine, appears to be the most commonly used formulation of phenylpropanolamine pharmaceutically.<ref name="Johnson1991" /><ref name="Elks2014" /><ref name="IndexNominum2000" /> Analogues of phenylpropanolamine include ephedrine, pseudoephedrine, amphetamine, methamphetamine, and cathinone.<ref name="LemkeWilliams2008" />

Phenylpropanolamine, structurally, is in the substituted phenethylamine class, consisting of a cyclic benzene or phenyl group, a two carbon ethyl moiety, and a terminal nitrogen, hence the name phen-ethyl-amine.<ref name="Westfall2" /> The methyl group on the alpha carbon (the first carbon before the nitrogen group) also makes this compound a member of the substituted amphetamine class.<ref name="Westfall2" /> Ephedrine is the N-methyl analogue of phenylpropanolamine.

Exogenous compounds in this family are degraded too rapidly by monoamine oxidase to be active at all but the highest doses.<ref name="Westfall2" /> However, the addition of the α-methyl group allows the compound to avoid metabolism and confer an effect.<ref name="Westfall2" /> In general, N-methylation of primary amines increases their potency, whereas β-hydroxylation decreases CNS activity, but conveys more selectivity for adrenergic receptors.<ref name="Westfall2">Template:Cite book</ref>

Phenylpropanolamine is a small-molecule compound with the molecular formula C₉H₁₃NO and a molecular weight of 151.21Template:Nbspg/mol.<ref name="PubChem">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="DrugBank">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It has an experimental log P of 0.67, while its predicted log P values range from 0.57 to 0.89.<ref name="PubChem" /><ref name="DrugBank" /> The compound is relatively lipophilic,<ref name="ChuaBenrimojTriggs1989">Template:Cite journal</ref> but is also more hydrophilic than other amphetamines.<ref name="BouchardWeberGeiger2002" /> The lipophilicity of amphetamines is closely related to their brain permeability.<ref name="BharateMignaniWishwakarma2018">Template:Cite journal</ref> For comparison to phenylpropanolamine, the experimental log P of methamphetamine is 2.1,<ref name="SchepSlaughterBeasley2010">Template:Cite journal</ref> of amphetamine is 1.8,<ref name="PubChem-Amphetamine">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="SchepSlaughterBeasley2010" /> of ephedrine is 1.1,<ref name="PubChem-Ephedrine">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> of pseudoephedrine is 0.7,<ref name="PubChem-Pseudoephedrine">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> of phenylephrine is -0.3,<ref name="PubChem-Phenylephrine">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> and of norepinephrine is -1.2.<ref name="PubChem-Norepinephrine">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Methamphetamine has high brain permeability,<ref name="SchepSlaughterBeasley2010" /> whereas phenylephrine and norepinephrine are peripherally selective drugs.<ref name="Eccles2007">Template:Cite journal</ref><ref name="FroeseDianGomez2020">Template:Cite journal</ref> The optimal log P for brain permeation and central activity is about 2.1 (range 1.5–2.7).<ref name="PajouheshLenz2005">Template:Cite journal</ref>

Phenylpropanolamine has been used pharmaceutically exclusively as the hydrochloride salt.<ref name="Elks2014" /><ref name="IndexNominum2000" />

History

Phenylpropanolamine was first synthesized in the early 20th century, in or around 1910.<ref name="Johnson1991">Template:Cite journal</ref><ref name="Ioannides-DemosProiettoTonkin2006" /> It was patented as a mydriatic in 1913.<ref name="Johnson1991" /> The pressor effects of phenylpropanolamine were characterized in the late 1920s and the 1930s.<ref name="Johnson1991" /> Phenylpropanolamine was first introduced for medical use by the 1930s.<ref name="Mersfelder2001" /><ref name="Ioannides-DemosProiettoTonkin2006" />

In the United States, phenylpropanolamine is no longer sold due to an increased risk of haemorrhagic stroke.<ref name="YoonBaeHong2007">Template:Cite journal</ref> In a few countries in Europe, however, it is still available either by prescription or sometimes over-the-counter. In Canada, it was withdrawn from the market on 31 May 2001.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It was voluntarily withdrawn from the Australian market by July 2001.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> In India, human use of phenylpropanolamine and its formulations was banned on 10 February 2011,<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> but the ban was overturned by the judiciary in September 2011.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Society and culture

Names

Phenylpropanolamine is the generic name of the drug and its Template:Abbrlink, Template:Abbrlink, and Template:Abbrlink, while phenylpropanolamine hydrochloride is its Template:Abbrlink and Template:Abbrlink in the case of the hydrochloride salt.<ref name="Elks2014">Template:Cite book</ref><ref name="IndexNominum2000">Template:Cite book</ref><ref name="MortonHall2012">Template:Cite book</ref><ref name="Drugs.com" /> It is also known by the synonym norephedrine.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="Drugs.com" />

Brand names of phenylpropanolamine include Acutrim, Appedrine, Capton Diet, Control, Dexatrim, Emagrin Plus A.P., Glifentol, Kontexin, Merex, Monydrin, Mydriatine, Prolamine, Propadrine, Propagest, Recatol, Rinexin, Tinaroc, and Westrim, among many others.<ref name="Elks2014" /><ref name="IndexNominum2000" /><ref name="Drugs.com">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> It has also been used in combinations under brand names including Allerest, Demazin, Dimetapp, and Sinarest, among others.<ref name="IndexNominum2000" /><ref name="Drugs.com" />

Availability

Phenylpropanolamine is available for medical and veterinary use in some countries.<ref name="IndexNominum2000" /><ref name="Drugs.com" />

Exercise and sports

There has been interest in phenylpropanolamine as a performance-enhancing drug in exercise and sports.<ref name="Jones2008">Template:Cite journal</ref> However, clinical studies suggest that phenylpropanolamine is not effective in this regard.<ref name="Jones2008" /><ref name="BouchardWeberGeiger2002">Template:Cite journal</ref> Phenylpropanolamine is not on the World Anti-Doping Agency (WADA) list of prohibited substances as of 2024.<ref name="WADA2024">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref>

Legal status

In Sweden, phenylpropanolamine is still available in prescription decongestants;<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> Phenylpropanolamine is also still available in Germany. It is used in some polypill medications like Wick DayMed capsules.

In the United Kingdom, phenylpropanolamine was available in many "all in one" cough and cold medications which usually also feature paracetamol (also known as acetaminophen) or another analgesic and caffeine and could also be purchased on its own. It is no longer approved for human use, however, and a European Category 1 Licence is required to purchase or acquire phenylpropanolamine for academic or research use.

In the United States, the Food and Drug Administration (FDA) issued a public health advisory<ref>Template:Cite press release</ref> recommending against the use of the drug in November 2000. In this advisory, the FDA requested but did not require that all drug companies discontinue marketing products containing phenylpropanolamine. The agency estimates that phenylpropanolamine caused between 200 and 500 strokes per year among 18-to-49-year-old users. In 2005, the FDA removed phenylpropanolamine from over-the-counter sale and removed its "generally recognized as safe and effective" (GRASE) status.<ref>Template:Cite press release</ref> Under the 2020 CARES Act, it requires FDA approval before it can be marketed again effectively banning the drug, even as a prescription.<ref>Over-the-Counter (OTC) Drug Review | OTC Monograph Reform in the CARES Act</ref>

Because of its potential use in amphetamine manufacture, phenylpropanolamine is controlled by the Combat Methamphetamine Epidemic Act of 2005. However, It is still available for veterinary use in dogs as a treatment for urinary incontinence.

Internationally, an item on the agenda of the 2000 Commission on Narcotic Drugs session called for including the stereoisomer norephedrine in Table I of United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.<ref>Template:Cite conference</ref>

Drugs containing phenylpropanolamine were banned in India on 27 January 2011.<ref>{{#invoke:citation/CS1|citation |CitationClass=web }}</ref> On 13 September 2011, Madras High Court revoked a ban on the manufacture and sale of pediatric drugs phenylpropanolamine and nimesulide.<ref>Template:Cite news</ref>

Veterinary use

Phenylpropanolamine is available for use in veterinary medicine.<ref name="DailyMed-Search" /> It is used to control urinary incontinence in dogs.<ref name="Gupta2012">Template:Cite book</ref><ref name="RivierePapich2009">Template:Cite book</ref>

In June 2024, the US Food and Drug Administration (FDA) approved Phenylpropanolamine hydrochloride chewable tablets for the control of urinary incontinence due to a weakening of the muscles that control urination (urethral sphincter hypotonus) in dogs.<ref name="FDA 20240611">{{#invoke:citation/CS1|citation |CitationClass=web }}</ref><ref name="Recent Animal Drug Approvals">{{#invoke:citation/CS1|citation |CitationClass=web }} Template:PD-notice</ref><ref>fda.gov</ref> This is the first generic phenylpropanolamine hydrochloride chewable tablets for dogs.<ref name="FDA 20240611" />

Urinary incontinence happens when a dog loses its ability to control when it urinates.<ref name="FDA 20240611" /> Urinary incontinence due to urethral sphincter hypotonus can happen as dogs age and as the dog’s muscle in its urethra (the tube that leads from the dog’s bladder to outside its body) weakens and loses control over its ability to hold urine.<ref name="FDA 20240611" />

Phenylpropanolamine hydrochloride chewable tablets contain the same active ingredient (phenylpropanolamine hydrochloride) in the same concentration and dosage form as the approved brand name drug product, Proin chewable tablets, which were first approved in August 2011.<ref name="FDA 20240611" /> In addition, the FDA determined that Phenylpropanolamine hydrochloride chewable tablets contain no inactive ingredients that may significantly affect the bioavailability of the active ingredient.<ref name="FDA 20240611" />

References

Template:Amphetamine Template:Nasal preparations Template:Appetite suppressants Template:Adrenergic receptor modulators Template:Monoamine releasing agents {{#invoke:Navbox|navbox}} Template:Chemical classes of psychoactive drugs Template:Portal bar Template:Authority control